CAR-T Therapy Shows Persistent Benefits in Young Leukemia … – P&T Community
|
CAR-T Therapy Shows Persistent Benefits in Young Leukemia …
P&T Community Updated results from a global clinical trial of the CAR T-cell therapy tisagenlecleucel (Kymriah, Novartis) show that children and young adults continued to show high rates of durable, complete remission of their high-risk form of acute lymphoblastic … |
